ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,307.01
-0.27%
US Tech 100
18,307.16
0.41%
다우존스 지수
39,671.04
-0.51%
Bitcoin
69,550.22
0.65%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 유럽
  5. EU
  6. Sanofi (SAN)

  7. Sanofi (SAN) 뉴스

SAN

Sanofi (SAN)

Sanofi
일자:
정렬 기준:
 검색 관련기사 보기:EU:SAN
일자시간출처헤드라인심볼기업
2024/05/2114:30GlobeNewswire Inc.Communiqué de presse : Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IAEU:SANSanofi
2024/05/2114:30GlobeNewswire Inc.Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaborationEU:SANSanofi
2024/05/2114:30GlobeNewswire Inc.Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaborationEU:SANSanofi
2024/05/2105:54GlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares - April 2024EU:SANSanofi
2024/05/2105:54GlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2024EU:SANSanofi
2024/05/2103:15GlobeNewswire Inc.Communiqué de presse : Présentation à l’ATS et publication dans le NEJM des données de dernière heure de l’étude confirmatoire de phase III NOTUS relative à Dupixent® dans le traitement de la BPCOEU:SANSanofi
2024/05/2103:15GlobeNewswire Inc.Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJMEU:SANSanofi
2024/05/2103:15GlobeNewswire Inc.Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJMEU:SANSanofi
2024/05/1314:00GlobeNewswire Inc.Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereigntyEU:SANSanofi
2024/05/1314:00GlobeNewswire Inc.Communiqué de presse : Sanofi investit plus d’un milliard d’euros supplémentaires dans la production de médicaments en France, en plus des 2,5 milliards d’euros déjà engagés dans de grands projets de souveraineté sanitaireEU:SANSanofi
2024/05/1314:00GlobeNewswire Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)EU:SANSanofi
2024/05/1015:00GlobeNewswire Inc.Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccinesEU:SANSanofi
2024/05/1015:00GlobeNewswire Inc.Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccinesEU:SANSanofi
2024/05/1015:00GlobeNewswire Inc.Communiqué de presse : Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19EU:SANSanofi
2024/05/0214:00GlobeNewswire Inc.Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizationsEU:SANSanofi
2024/05/0214:00GlobeNewswire Inc.Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizationsEU:SANSanofi
2024/05/0101:00GlobeNewswire Inc.Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2024EU:SANSanofi
2024/05/0101:00GlobeNewswire Inc.Press Release: Annual General Meeting of April 30, 2024EU:SANSanofi
2024/05/0101:00GlobeNewswire Inc.Press Release: Annual General Meeting of April 30, 2024EU:SANSanofi
2024/04/2514:30GlobeNewswire Inc.Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidanceEU:SANSanofi
2024/04/2514:30GlobeNewswire Inc.Communiqué de presse : Sanofi réitère ses objectifs financiers pour 2024, après une forte croissance de 7% portée par les lancementsEU:SANSanofi
2024/04/2314:00GlobeNewswire Inc.Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopeniaEU:SANSanofi
2024/04/2314:00GlobeNewswire Inc.Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopeniaEU:SANSanofi
2024/04/2314:00GlobeNewswire Inc.Communiqué de presse : L’étude de phase III LUNA 3 du rilzabrutinib pour le traitement de la thrombocytopénie immune a atteint son critère d’évaluation primaireEU:SANSanofi
2024/04/1714:00GlobeNewswire Inc.Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosisEU:SANSanofi
2024/04/1714:00GlobeNewswire Inc.Communiqué de presse : De nouveaux résultats de phase II à 48 semaines relatifs au frexalimab confortent le potentiel d'efficacité élevée et durable dans le traitement de la sclérose en plaquesEU:SANSanofi
2024/04/1714:00GlobeNewswire Inc.Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosisEU:SANSanofi
2024/04/1303:05GlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mars 2024EU:SANSanofi
2024/04/1303:05GlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares - March 2024EU:SANSanofi
2024/04/0901:00GlobeNewswire Inc.Sanofi - AGM 30.04.2024 - Availability of Preparatory documentsEU:SANSanofi
 검색 관련기사 보기:EU:SAN

최근 히스토리

BIT
P1W4U5
NLBNPIT1W4U5 20240920 1800
BIT
P1ZVA4
NLBNPIT1ZVA4 20991231 21...
TSX
CPD
iShares S&P TSX Canadian...
EU
RGBH
Bretagne Region Brittany...
BITMOT
982291
Schatz Tf 2,8% Gn25 Eur
LSE
32LO
Municplty Nts08
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유